And, to avoid structural liabilities, Fusion Antibodies utilizes state-of-the-art three-dimensional (3D) protein structural modeling tools, rather than relying on guesswork for epitope prediction.

Shares of Fusion Antibodies plc (LON:FAB – Get Free Report) reached a new 52-week high on Friday . The company traded as high as GBX 10.25 ($0.13) and last traded at GBX 10.23 ($0.13), with a volume ...

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. Receive News & Ratings for Fusion ...

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase transition ...